Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in ...

CNBC's Angelica Peebles and AstraZeneca CEO Pascal Soriot join 'Squawk Box' to discuss the company's breast cancer drug trial ...

CHICAGO -- The neurokinin-targeted agent elinzanetant significantly reduced the frequency of hot flashes among women ...

CHICAGO -- Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing commitment to enhancing therapeutic options for HER2-positive metastatic breast ...

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...

AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

A new study, sponsored by AstraZeneca and presented at the American Society of Clinical Oncology (ASCO) annual meeting in ...

A trial funded by AstraZeneca found the drug is effective in stopping cancer cells from using hormones to grow ...